BioPharma Resources

NDA 213976 · Takeda Pharms USA

Eohilia

Budesonide · Oral · Corticosteroid

Breakthrough therapyPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: May 16, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Feb 9, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

592

206 Phase 3, 32 recruiting

FAERS reports

40,872

31,603 serious, 3,109 with death reported

AI brief across all sources

Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 3, 2025.

EOHILIA ™ is indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE). Limitations of Use EOHILIA has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks [see Dosage and Administration (2.1) , Clinical Studies (14) ]. EOHILIA is a corticosteroid indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE). ( 1 ) Limitations of Use EOHILIA has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks. ( 1 , 2.1 , 14 )

Mechanism: Budesonide is an anti-inflammatory corticosteroid and has a high glucocorticoid effect and a weak mineralocorticoid effect, and the affinity of budesonide to glucocorticoid receptors, which reflects the intrinsic potency of the drug, is about 200-fold that of cortisol and 15-fold that of prednisolone. The precise mechanism of corticosteroid actions on inflammation in EoE is not known. Inflammation is an important component in the pathogenesis of EoE. Corticosteroids have a wide range of inhibitory activities against multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 9, 2024 Original approval · Type 3 - New Dosage Form · priority review Breakthrough therapyOrphanLabelLetterReview
1 products under this application
  • EOHILIA · BUDESONIDE 2MG/10ML · SUSPENSION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Budesonide" as an intervention, any sponsor and status, largest first.

All 592 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective4,932
  • dyspnoea4,578
  • off label use4,454
  • asthma3,631
  • fatigue2,606
  • condition aggravated2,494
  • headache2,444
  • diarrhoea2,391
  • cough2,247
  • pneumonia2,247
  • nausea2,115
  • wheezing2,025

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004138
2005220
2006195
2007197
2008282
2009292
2010320
2011533
2012736
2013782
2014978
20151,346
20161,591
20171,682
20182,259
20192,940
20203,524
20213,719
20224,003
20233,975
20244,199
20254,082
20262,879

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Eohilia (Budesonide)

2024 spending

$1.6M

Beneficiaries

440

776 claims

Per beneficiary

$3,531

$3.03 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$1,553,442

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,119 on PubMed

Sponsor: Takeda

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.